Navigation Links
Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
Date:10/21/2011

CORAL SPRINGS, Fla., Oct. 21, 2011 /PRNewswire/ -- Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and 2 mg, the generic version of Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, Inc. Glycopyrrolate tablets are intended for use as adjunctive therapy in the treatment of peptic ulcers.

"We're up to our third approval this year," said Robert Edwards, CEO of Boca Pharmacal.  "Each approval – including Glycopyrrolate Tablets – has been consistent with our mission to pursue and provide products to the marketplace that are important to our customers, but may be overlooked by some of the huge multinationals. We're continuing to file new ANDAs, and will keep doing so in our ongoing effort to provide the generic products our customers – and their patients – need."

Boca Pharmacal, Inc.

Since its beginnings in 1998, Boca Pharmacal's mission has been to offer niche items that were overlooked by some of the larger generic companies as affordable alternatives to brand-named products.

Using multiple facilities across the globe, Boca Pharmacal has a broad reach and a reliable vertical structure that allows them to develop products that include tablets and capsules, semi-solids, solutions, and suspensions. They continue to invest in research and development to make sure they're providing their clients with a wide variety of offerings. The Boca Pharmacal product line is marketed to chains, wholesalers, distributors, managed markets and government agencies.  Boca Pharmacal is located at 3550 NW 126th Avenue, Coral Springs, Florida, 33065. For more information visit www.bocapharmacal.com.CONTACT:

Jennifer MouraBoca Pharmacal3550 NW 126th AveCoral Springs, FL 33065Phone: (954) 346-8810Email: info@bocapharmacal.com
'/>"/>

SOURCE Boca Pharmacal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
2. Mission Pharmacal Launches New Vitamin B6-Rich Prescription Prenatal Vitamin, CitraNatal(R) B-Calm
3. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
4. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  BioAtla, ... the development of Conditionally Active Biologic (CAB) ... Beijing Sinobioway Group Company, Limited (Sinobioway) selected ... development.  The specific program candidates and the ... 2015, BioAtla and Sinobioway entered into a ...
(Date:12/5/2016)... 2016 United Kingdom Ophthalmic Diagnostic Equipment ... new report, "United Kingdom Ophthalmic Diagnostic Equipment Market ... the United Kingdom Ophthalmic Diagnostic Equipment market. The ... volume (in units) and average prices (USD) within ... Ultrasound Imaging Systems, Corneal Topography Systems, Ophthalmoscopes, Perimeters, ...
(Date:12/5/2016)... INTRODUCTION Since the ... as a crucial class of pharmacological interventions responsible ... are also used for prophylactic purposes in patients ... patients undergoing chemotherapy). However, the inappropriate use of ... rapidly accelerated an evolutionary response of antibiotic drug ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 2016 , ... The Behavioral Health Center of Excellence (BHCOE) ... as a top behavioral service provider in the country. The award celebrates exceptional ... and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging audit, ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... thrilled to formally announce its Not a Moment to Lose fundraising campaign. As ... rally supporters dedicated to declaring victory over cancer. The campaign aims to raise ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder ... one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water ...
Breaking Medicine News(10 mins):